Wiley Blackwell

SHERPA: Unknown

People

  1. Zelenetz
    Zelenetz
  2. Kumar
    Kumar
  3. Noy
    Noy
  4. Hamlin
    Hamlin
  5. Moskowitz
    Moskowitz
  6. Palomba
    Palomba
  7. Horwitz
    Horwitz
  8. Yahalom
    Yahalom
  9. Dogan
    Dogan
  10. Schoder
    Schoder

Groups

  1. Center for Hematologic Malignancies (29)
  2. Department of Medicine (29)
  3. Hematologic Malignancies, Division of (29)
  4. Lymphoma (29)
  5. Survivorship Research (16)
  6. Hematology-Oncology Fellows (14)
  7. Epidemiology and Biostatistics (11)
  8. Executive Committee, Center for Hematologic Malignancies (11)
  9. Biostatistics Service (10)
  10. Population Sciences Research Program (10)
Search Within
  1. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (7)
  3. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (29)
  2. Department of Medicine (29)
  3. Hematologic Malignancies, Division of (29)
  4. Lymphoma (29)
  5. Survivorship Research (16)
  6. Hematology-Oncology Fellows (14)

More Groups

People
  1. Andrew Zelenetz (29)
  2. Anita Kumar (14)
  3. David Straus (14)
  4. Ariela Noy (13)
  5. Paul Hamlin (12)
  6. Alison Moskowitz (11)

More People

Years
  1. 2023 (6)
  2. 2021 (3)
  3. 2019 (5)
  4. 2017 (7)
  5. 2016 (1)
  6. 2015 (1)

More Years

Publications
  1. Hematological Oncology (21)
  2. Cancer (7)
  3. Cancer Consult: Expertise for Clinical Practice (1)

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A.; Salles, G.; Yahalom, J.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK‐inhibitor pre‐treated mantle cell lymphoma: Updated results, subgroup analysis from bruin with >3 years follow‐up from start of enrollment
    Meeting Abstract

    Cheah, C. Y.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; Alencar, A. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Zandelisib, a PI3Kδ inhibitor on intermittent schedule (IS) in follicular lymphoma patients who progressed within 24 months of first‐line chemoimunotherapy (POD24)
    Meeting Abstract

    Pagel, J.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H.; Kenkre, V. P.; Soumerai, J. D.; Llorin‐Sangalang, J.; Gorbatchevsky, I.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A pivotal, randomized, double-blind, placebo-controlled, two-arm, phase 2 study of ME‐401 investigating two dosing schedules in patients with follicular lymphoma (FL) after failure of two or more prior systemic therapies
    Meeting Abstract

    Zelenetz, A.; Zinzani, P.; Buske, C.; Ribrag, V.; Cunningham, D.; Jurczak, W.; Abrisqueta, P.; Agajanian, R.; Chaudhry, A.; Kayyal, T.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save